Hyperkalemia

Suboptimal RAASi Therapy After Hyperkalemia Ups Cardiorenal Risks

Publish Date February 28, 2023

Guidelines support the use of RAASi at the maximum tolerated dose in patients with CKD and heart failure.

Weak Association Found Between Dietary, Serum Potassium in CKD

Publish Date February 8, 2023

Study findings do not support eliminating potassium-containing foods from the diet to manage hyperkalemia.

Longer Potassium Binder Use May Decrease Hyperkalemia-Related Hospitalization

Publish Date January 23, 2023

Hyperkalemia is associated with increased health care resource utilization.

SGLT2 Inhibitor Plus MRA May Further Reduce Cardiovascular Risks

Publish Date January 3, 2023

SGLT2 inhibitors and MRAs might provide complementary effects for organ protection, according to investigators.

Trimethoprim-Sulfamethoxazole vs Amoxicillin Ups Hyperkalemia Risk

Publish Date December 9, 2022

Trimethoprim-sulfamethoxazole is mostly excreted through the kidneys, and it can cause hyperkalemia by reducing potassium excretion.

Sodium Zirconium Cyclosilicate Reduces Tacrolimus Absorption

Publish Date December 7, 2022

Tacrolimus exposure was reduced by approximately one-third when it was co-administered with the potassium binder sodium zirconium cyclosilicate, investigators reported.

Continuing ACE Inhibitors Despite Potassium Change Can Have Benefits

Publish Date November 21, 2022

Stopping renin-angiotensin-aldosterone inhibitors after hyperkalemia may offset their potential clinical benefits, according to investigators.

Patiromer Use for Acute Hyperkalemia Characterized

Publish Date November 18, 2022

Investigators report a low incidence of hypokalemia and hypomagnesemia after a single dose of patiromer monotherapy.

Potassium Binder Use Long Term Linked With Better Outcomes

Publish Date November 17, 2022

Potassium binders historically have been used short term or intermittently.

RAAS Inhibitor Discontinuation After Hyperkalemia Tied to Adverse Outcomes

Publish Date November 16, 2022

Discontinuation of RAAS inhibitors is often the first approach to manage hyperkalemia.